JP2014522841A5 - - Google Patents

Download PDF

Info

Publication number
JP2014522841A5
JP2014522841A5 JP2014519088A JP2014519088A JP2014522841A5 JP 2014522841 A5 JP2014522841 A5 JP 2014522841A5 JP 2014519088 A JP2014519088 A JP 2014519088A JP 2014519088 A JP2014519088 A JP 2014519088A JP 2014522841 A5 JP2014522841 A5 JP 2014522841A5
Authority
JP
Japan
Prior art keywords
oil
item
water emulsion
composition
mol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014519088A
Other languages
English (en)
Japanese (ja)
Other versions
JP6120839B2 (ja
JP2014522841A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/045845 external-priority patent/WO2013006837A1/en
Publication of JP2014522841A publication Critical patent/JP2014522841A/ja
Publication of JP2014522841A5 publication Critical patent/JP2014522841A5/ja
Application granted granted Critical
Publication of JP6120839B2 publication Critical patent/JP6120839B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014519088A 2011-07-06 2012-07-06 カチオン性水中油型エマルジョン Expired - Fee Related JP6120839B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161505109P 2011-07-06 2011-07-06
US61/505,109 2011-07-06
US201161545936P 2011-10-11 2011-10-11
US61/545,936 2011-10-11
US201261585641P 2012-01-11 2012-01-11
US61/585,641 2012-01-11
PCT/US2012/045845 WO2013006837A1 (en) 2011-07-06 2012-07-06 Cationic oil-in-water emulsions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016156141A Division JP2016210792A (ja) 2011-07-06 2016-08-09 カチオン性水中油型エマルジョン

Publications (3)

Publication Number Publication Date
JP2014522841A JP2014522841A (ja) 2014-09-08
JP2014522841A5 true JP2014522841A5 (cg-RX-API-DMAC10.html) 2015-08-20
JP6120839B2 JP6120839B2 (ja) 2017-04-26

Family

ID=46604537

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014519088A Expired - Fee Related JP6120839B2 (ja) 2011-07-06 2012-07-06 カチオン性水中油型エマルジョン
JP2016156141A Withdrawn JP2016210792A (ja) 2011-07-06 2016-08-09 カチオン性水中油型エマルジョン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016156141A Withdrawn JP2016210792A (ja) 2011-07-06 2016-08-09 カチオン性水中油型エマルジョン

Country Status (12)

Country Link
US (3) US9636410B2 (cg-RX-API-DMAC10.html)
EP (2) EP2729124B1 (cg-RX-API-DMAC10.html)
JP (2) JP6120839B2 (cg-RX-API-DMAC10.html)
CN (1) CN103796639B (cg-RX-API-DMAC10.html)
AU (2) AU2012280904B2 (cg-RX-API-DMAC10.html)
BR (1) BR112014000235A8 (cg-RX-API-DMAC10.html)
CA (1) CA2840965C (cg-RX-API-DMAC10.html)
ES (1) ES2702318T3 (cg-RX-API-DMAC10.html)
MX (1) MX350258B (cg-RX-API-DMAC10.html)
RU (1) RU2649133C2 (cg-RX-API-DMAC10.html)
SG (1) SG10201605500TA (cg-RX-API-DMAC10.html)
WO (1) WO2013006837A1 (cg-RX-API-DMAC10.html)

Families Citing this family (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3243526T (pt) 2010-07-06 2020-03-04 Glaxosmithkline Biologicals Sa Distribuição de arn para despoletar múltiplas vias imunitárias
US10487332B2 (en) 2010-07-06 2019-11-26 Glaxosmithkline Biologicals Sa Immunisation of large mammals with low doses of RNA
CN103153284B (zh) 2010-07-06 2015-11-25 诺华股份有限公司 含有其pKa值有利于RNA递送的脂质的脂质体
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
JP5911870B2 (ja) 2010-08-31 2016-04-27 ノバルティス アーゲー 免疫原をコードするｒｎａの送達のためのｐｅｇ化リポソーム
EP2857499A1 (en) 2010-10-01 2015-04-08 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
KR102266691B1 (ko) 2010-10-11 2021-06-23 노파르티스 아게 항원 전달 플랫폼
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
KR20220025112A (ko) 2011-06-08 2022-03-03 샤이어 휴먼 지네틱 테라피즈 인크. Mrna 전달을 위한 지질 나노입자 조성물 및 방법
US9636410B2 (en) 2011-07-06 2017-05-02 Glaxosmithkline Biologicals Sa Cationic oil-in-water emulsions
JP2014522842A (ja) 2011-07-06 2014-09-08 ノバルティス アーゲー 免疫原性組み合わせ組成物およびその使用
US9655845B2 (en) 2011-07-06 2017-05-23 Glaxosmithkline Biologicals, S.A. Oil-in-water emulsions that contain nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PT3682905T (pt) 2011-10-03 2022-04-07 Modernatx Inc Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
ES2923757T3 (es) 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
AU2013286093B2 (en) * 2012-07-06 2018-01-04 Novartis Ag Complexes of cytomegalovirus proteins
US9512456B2 (en) 2012-08-14 2016-12-06 Modernatx, Inc. Enzymes and polymerases for the synthesis of RNA
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
AU2014204826A1 (en) 2013-01-10 2015-07-09 Seqirus UK Limited Influenza virus immunogenic compositions and uses thereof
ES2498521B1 (es) * 2013-02-20 2015-08-18 Fundación Pública Andaluza Para La Investigación De Málaga En Biomedicina Y Salud (Fimabis) Formulaciones basadas en nanoemulsiones y su uso para el tratamiento de la obesidad
US20160024181A1 (en) 2013-03-13 2016-01-28 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
PL2970948T3 (pl) 2013-03-15 2019-06-28 Glaxosmithkline Biologicals Sa Sposoby oczyszczania rna
ES2749223T3 (es) 2013-04-16 2020-03-19 Univ Cincinnati Composiciones antimicrobianas de antibióticos aminoglicosídicos y quelantes de iones de zinc
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
IL310015B2 (en) * 2013-12-31 2026-02-01 Access To Advanced Health Inst Single vial formulation
US10842859B2 (en) 2014-03-25 2020-11-24 Yale University Uses of parasite macrophage migration inhibitory factors
HRP20220070T1 (hr) 2014-04-23 2022-04-01 Modernatx, Inc. Cjepiva nukleinske kiseline
EP3134117A1 (en) * 2014-04-23 2017-03-01 Institute for Research in Biomedicine Human cytomegalovirus vaccine compositions and method of producing the same
WO2015165480A1 (en) * 2014-04-30 2015-11-05 Institute For Research In Biomedicine Human cytomegalovirus vaccine compositions and method of producing the same
EP2974739A1 (en) 2014-07-15 2016-01-20 Novartis AG RSVF trimerization domains
US10350165B2 (en) 2014-12-12 2019-07-16 Ojai Energetics Pbc Methods and systems for forming stable droplets
EP3048114A1 (en) 2015-01-22 2016-07-27 Novartis AG Cytomegalovirus antigens and uses thereof
EP3061826A1 (en) 2015-02-27 2016-08-31 Novartis AG Flavivirus replicons
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
MA42502A (fr) 2015-07-21 2018-05-30 Modernatx Inc Vaccins contre une maladie infectieuse
JP7028774B2 (ja) * 2015-08-19 2022-03-02 シャンハイ ギンポサム ファーマテック カンパニー リミテッド ギンセノシドを膜材料として有するリポソームならびにその調製および使用
HRP20220156T1 (hr) 2015-09-17 2022-04-15 Modernatx, Inc. Spojevi i pripravci za unutarstaničnu isporuku terapeutskih sredstava
EP3359670B2 (en) 2015-10-05 2024-02-14 ModernaTX, Inc. Methods for therapeutic administration of messenger ribonucleic acid drugs
EP3364949A4 (en) 2015-10-22 2019-07-31 ModernaTX, Inc. CANCER VACCINES
SG11201803360UA (en) * 2015-10-22 2018-05-30 Modernatx Inc Nucleic acid vaccines for varicella zoster virus (vzv)
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
EP3364981A4 (en) * 2015-10-22 2019-08-07 ModernaTX, Inc. VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
US20180271970A1 (en) * 2015-10-22 2018-09-27 Modernatx, Inc. Respiratory syncytial virus vaccine
MA45209A (fr) 2015-10-22 2019-04-17 Modernatx Inc Vaccins contre les maladies sexuellement transmissibles
DK3386484T3 (da) 2015-12-10 2022-07-04 Modernatx Inc Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler
RS63051B1 (sr) 2015-12-22 2022-04-29 Modernatx Inc Jedinjenja i kompozicije za intracelularnu isporuku agenasa
CN107190050B (zh) * 2016-03-14 2020-10-27 华东理工大学 一种hrp活性测定及h2o2浓度检测的试剂盒及其应用
WO2017162265A1 (en) 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Trans-replicating rna
WO2017162266A1 (en) 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Rna replicon for versatile and efficient gene expression
WO2017208191A1 (en) 2016-06-02 2017-12-07 Glaxosmithkline Biologicals Sa Zika viral antigen constructs
WO2018060288A1 (en) 2016-09-29 2018-04-05 Glaxosmithkline Biologicals S.A. Compositions and methods of treatment of persistent hpv infection
GB201616904D0 (en) 2016-10-05 2016-11-16 Glaxosmithkline Biologicals Sa Vaccine
EP3538067A1 (en) 2016-11-08 2019-09-18 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
MA46766A (fr) 2016-11-11 2019-09-18 Modernatx Inc Vaccin antigrippal
EP3541416A1 (en) 2016-11-17 2019-09-25 GlaxoSmithKline Biologicals SA Zika viral antigen constructs
EP3551193A4 (en) 2016-12-08 2020-08-19 Modernatx, Inc. NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES
US20180216022A1 (en) * 2017-01-27 2018-08-02 Scott Rettberg System and method for reducing friction, torque and drag in artificial lift systems used in oil and gas production wells
JP7332478B2 (ja) 2017-03-15 2023-08-23 モデルナティエックス インコーポレイテッド 脂質ナノ粒子製剤
WO2018170270A1 (en) * 2017-03-15 2018-09-20 Modernatx, Inc. Varicella zoster virus (vzv) vaccine
WO2018170322A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Crystal forms of amino lipids
US11576961B2 (en) 2017-03-15 2023-02-14 Modernatx, Inc. Broad spectrum influenza virus vaccine
WO2018170260A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Respiratory syncytial virus vaccine
RS63953B1 (sr) 2017-03-15 2023-02-28 Modernatx Inc Jedinjenje i kompozicije za intracelularnu isporuku terapeutskih sredstava
WO2018170256A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Herpes simplex virus vaccine
WO2018170347A1 (en) 2017-03-17 2018-09-20 Modernatx, Inc. Zoonotic disease rna vaccines
EP3638678B1 (en) 2017-06-14 2025-12-03 ModernaTX, Inc. Compounds and compositions for intracellular delivery of agents
MA49421A (fr) 2017-06-15 2020-04-22 Modernatx Inc Formulations d'arn
AU2018285694B2 (en) * 2017-06-15 2025-04-10 Access To Advanced Health Institute Nanostructured lipid carriers and stable emulsions and uses thereof
MX2020002348A (es) 2017-08-31 2020-10-08 Modernatx Inc Métodos de elaboración de nanopartículas lipídicas.
AU2018333530B2 (en) 2017-09-13 2024-05-30 Biontech Cell & Gene Therapies Gmbh RNA replicon for expressing a T cell receptor or an artificial T cell receptor
US12291717B2 (en) 2017-09-13 2025-05-06 Biontech Rna Pharmaceuticals Gmbh RNA replicon for reprogramming somatic cells
EP3681514A4 (en) 2017-09-14 2021-07-14 ModernaTX, Inc. RNA VACZINE AGAINST ZIKA VIRUS
EP3461497A1 (en) 2017-09-27 2019-04-03 GlaxoSmithKline Biologicals S.A. Viral antigens
US20190137035A1 (en) 2017-11-03 2019-05-09 Scott Rettberg System and method for reducing friction, torque and drag in artificial lift systems used in oil and gas production wells
KR20240134250A (ko) 2018-01-04 2024-09-06 아이코닉 테라퓨틱스, 인코포레이티드 항-조직 인자 항체, 항체-약물 결합체, 및 관련 방법
US11911453B2 (en) 2018-01-29 2024-02-27 Modernatx, Inc. RSV RNA vaccines
AU2019321186B2 (en) 2018-08-17 2024-05-23 Glaxosmithkline Biologicals Sa Immunogenic compositions and uses thereof
US12151029B2 (en) 2018-09-19 2024-11-26 Modernatx, Inc. PEG lipids and uses thereof
EP3853202A1 (en) 2018-09-19 2021-07-28 ModernaTX, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
CN112996854B (zh) 2018-09-19 2024-08-30 摩登纳特斯有限公司 高纯度peg脂质和其用途
US12090235B2 (en) 2018-09-20 2024-09-17 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
WO2020144295A1 (en) 2019-01-10 2020-07-16 Biontech Rna Pharmaceuticals Gmbh Localized administration of rna molecules for therapy
CN113939282A (zh) 2019-01-31 2022-01-14 摩登纳特斯有限公司 制备脂质纳米颗粒的方法
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
MA55321A (fr) 2019-03-15 2022-01-19 Modernatx Inc Vaccins à base d'arn contre le vih
MX2022000879A (es) * 2019-07-21 2022-05-02 Glaxosmithkline Biologicals Sa Vacuna viral terapeutica.
AU2020351220A1 (en) 2019-09-19 2022-04-07 Modernatx, Inc. Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents
EP4031524A1 (en) 2019-09-19 2022-07-27 ModernaTX, Inc. Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
CN110643632B (zh) * 2019-09-26 2022-06-10 中国科学院武汉病毒研究所 一种基于甲病毒复制子载体的狂犬病毒感染性克隆及制备方法和应用
EP3819377A1 (en) 2019-11-08 2021-05-12 Justus-Liebig-Universität Gießen Circular rna and uses thereof for inhibiting rna-binding proteins
KR102764120B1 (ko) * 2019-12-31 2025-02-06 엘릭서젠 쎄라퓨틱스, 인크. 핵산 및 단백질의 세포 및 조직으로의 온도-기반 일시적 전달
JP2023517644A (ja) 2020-03-09 2023-04-26 アークトゥラス・セラピューティクス・インコーポレイテッド コロナウイルスワクチン組成物及び方法
US12569553B2 (en) 2020-03-09 2026-03-10 Dynavax Technologies Corporation Shingles vaccines comprising a TLR9 agonist
US20230364219A1 (en) 2020-04-16 2023-11-16 Glaxosmithkline Biologicals Sa Sars cov-2 spike protein construct
JP7769644B2 (ja) 2020-06-04 2025-11-13 バイオエヌテック エスエー 多用途かつ効率的な遺伝子発現のためのｒｎａレプリコン
WO2021245611A1 (en) 2020-06-05 2021-12-09 Glaxosmithkline Biologicals Sa Modified betacoronavirus spike proteins
EP4171629A1 (en) 2020-06-29 2023-05-03 GlaxoSmithKline Biologicals S.A. Adjuvants
US12178921B2 (en) 2020-08-14 2024-12-31 Arcturus Therapeutics, Inc. Method of lyophilizing lipid nanoparticles
AU2021392077A1 (en) * 2020-12-02 2023-07-13 Seqirus Inc. Multicistronic rna vaccines and uses thereof
EP4008785A1 (en) 2020-12-03 2022-06-08 Justus-Liebig-Universität Gießen Circular nucleic acids and uses thereof for interfering with genome expression and proliferation of coronaviruses
US20240301006A1 (en) 2020-12-23 2024-09-12 Glaxosmithkline Biologicals Sa Self-amplifying messenger rna
AU2022208435A1 (en) 2021-01-18 2023-08-10 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof
EP4032546A1 (en) 2021-01-20 2022-07-27 GlaxoSmithKline Biologicals S.A. Therapeutic viral vaccine
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
EP4313152A1 (en) 2021-03-26 2024-02-07 GlaxoSmithKline Biologicals S.A. Immunogenic compositions
BR112023022548A2 (pt) * 2021-04-30 2024-01-02 Samyang Holdings Corp Kit para preparar nanopartículas contendo fármaco
US20240285755A1 (en) 2021-05-24 2024-08-29 Glaxosmithkline Biologicals Sa Adjuvants
WO2022259191A1 (en) 2021-06-09 2022-12-15 Glaxosmithkline Biologicals Sa Release assay for determining potency of self-amplifying rna drug product and methods for using
IN202121031414A (cg-RX-API-DMAC10.html) * 2021-07-13 2023-01-13
WO2023020994A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020993A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020992A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
US20250236883A1 (en) 2021-10-18 2025-07-24 BioNTech SE Modified replicable rna and related compositions and their use
EP4419708A1 (en) 2021-10-18 2024-08-28 BioNTech SE Methods for determining mutations for increasing modified replicable rna function and related compositions and their use
CN114316130B (zh) * 2021-12-27 2023-04-25 爱森（中国）絮凝剂有限公司 工业生产二甲基二烯丙基氯化铵副产氯化钠在阳离子乳液中的利用方法
WO2023159036A1 (en) * 2022-02-16 2023-08-24 The Cleveland Clinic Foundation Amhr2-ed cancer vaccine formulations
WO2023192876A1 (en) * 2022-03-28 2023-10-05 Reilly Steve E Composition to increase cellular longevity
WO2023213378A1 (en) 2022-05-02 2023-11-09 BioNTech SE Replicon compositions and methods of using same for the treatment of diseases
WO2024017479A1 (en) 2022-07-21 2024-01-25 BioNTech SE Multifunctional cells transiently expressing an immune receptor and one or more cytokines, their use and methods for their production
WO2024056856A1 (en) 2022-09-15 2024-03-21 BioNTech SE Systems and compositions comprising trans-amplifying rna vectors with mirna
EP4458968A1 (en) 2023-05-05 2024-11-06 Justus-Liebig-Universität Gießen Circular nucleic acids and uses thereof for shaping the cellular proteome
CR20250529A (es) * 2023-06-09 2026-01-12 Merck Sharp & Dohme Llc Composiciones adyuvantes en nanoemulsión para vacunas contra el papilomavirus humano
WO2025040709A1 (en) 2023-08-24 2025-02-27 BioNTech SE Systems and compositions comprising highly active trans-amplifying replicases
WO2025051381A1 (en) 2023-09-08 2025-03-13 BioNTech SE Methods and compositions for localized expression of administered rna
WO2025244961A1 (en) * 2024-05-22 2025-11-27 Merck Sharp & Dohme Llc Processes for making stable nanoemulsion adjuvants

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA583561A (en) 1959-09-22 H. Edgerton William Therapeutically valuable esters and methods for obtaining the same
FR1317586A (cg-RX-API-DMAC10.html) 1961-03-17 1963-05-08
US3906092A (en) 1971-11-26 1975-09-16 Merck & Co Inc Stimulation of antibody response
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US5132418A (en) 1980-02-29 1992-07-21 University Patents, Inc. Process for preparing polynucleotides
IE51913B1 (en) 1980-10-09 1987-04-29 Mars G B Ltd Thermo irreversible gelling system and edible materials based thereon
US4973679A (en) 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
US4668777A (en) 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
US4373071A (en) 1981-04-30 1983-02-08 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
CA1341482C (en) 1984-10-31 2005-05-10 Paul A. Luciw Process for preparing fragments of aids-associated retroviruses
US4689225A (en) 1984-11-02 1987-08-25 Institut Merieux Vaccine for cytomegalovirus
US5153319A (en) 1986-03-31 1992-10-06 University Patents, Inc. Process for preparing polynucleotides
DK341386D0 (da) 1986-07-18 1986-07-18 Voetman Karin Glassau Fremgangsmaade og apparat til oprulning af flade dejstykker, f.eks. til roulader
ES2053549T3 (es) 1986-08-11 1994-08-01 Innovata Biomed Ltd Un proceso para la preparacion de una formulacion farmaceutica apropiada para inhalacion.
US5906980A (en) 1987-07-17 1999-05-25 Hem Research Inc. Treatment of hepatitis with mismatched dsRNA
US5712257A (en) 1987-08-12 1998-01-27 Hem Research, Inc. Topically active compositions of mismatched dsRNAs
WO1989004669A1 (en) 1987-11-18 1989-06-01 Chiron Corporation Nanbv diagnostics and vaccines
EP0436537A4 (en) 1988-01-29 1992-04-08 Chiron Corporation Recombinant cmv neutralizing proteins
US5262530A (en) 1988-12-21 1993-11-16 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5047524A (en) 1988-12-21 1991-09-10 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
HUT54896A (en) 1989-03-17 1991-04-29 Chiron Corp Process for producing aquous diagnosticum and vaccine of nanbv
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
KR0185426B1 (ko) 1991-06-24 1999-04-01 로버트 피. 블랙버언 씨형 간염 바이러스 폴리펩티드
DK0608261T3 (da) 1991-09-13 2003-03-17 Chiron Corp Sammensætninger med immunreaktivt hepatitis C virus polypeptid
JPH09500013A (ja) 1993-06-01 1997-01-07 ライフ・テクノロジーズ・インコーポレイテッド カチオン性脂質による遺伝子免疫
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US6040295A (en) 1995-01-13 2000-03-21 Genemedicine, Inc. Formulated nucleic acid compositions and methods of administering the same for gene therapy
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5700642A (en) 1995-05-22 1997-12-23 Sri International Oligonucleotide sizing using immobilized cleavable primers
US6120794A (en) 1995-09-26 2000-09-19 University Of Pittsburgh Emulsion and micellar formulations for the delivery of biologically active substances to cells
JP2001503735A (ja) 1996-07-03 2001-03-21 ユニバーシティ オブ ピッツバーグ 親水性活性試薬のためのエマルジョン処方物
EP0938298B1 (en) 1996-09-13 2002-12-04 Lipoxen Technologies Limited Liposome-based composition
ES2195317T3 (es) 1997-01-30 2003-12-01 Chiron Corp Uso de microparticulas con antigeno adsorbido para estimular respuestas inmunitarias.
WO2000006123A1 (en) 1998-07-29 2000-02-10 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
US6884435B1 (en) 1997-01-30 2005-04-26 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
CA2295740A1 (en) 1997-07-08 1999-01-21 Chiron Corporation Use of submicron oil-in-water emulsions with dna vaccines
PT1042001E (pt) 1997-12-16 2002-09-30 Chiron Corp Uso de microparticulas combinadas com emulsoes submicronicas oleo-em-agua
US6218371B1 (en) 1998-04-03 2001-04-17 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
JP2002521423A (ja) * 1998-07-31 2002-07-16 コリア インスティチュート オブ サイエンス アンド テクノロージ 遺伝子又は薬物運搬体としての脂質エマルジョン及び固形脂質微粒子
US20020142974A1 (en) 1998-09-11 2002-10-03 Leonard D. Kohn Immune activation by double-stranded polynucleotides
US6770282B1 (en) 1998-10-23 2004-08-03 Heska Corporation Cationic lipid-mediated enhancement of nucleic acid immunization of cats
WO2000050006A2 (en) 1999-02-26 2000-08-31 Chiron Corporation Microemulsions with adsorbed macromoelecules and microparticles
AP1891A (en) 1999-05-06 2008-09-23 The Immune Response Corp HIV immunogenic compositions and methods.
WO2001022972A2 (en) * 1999-09-25 2001-04-05 University Of Iowa Research Foundation Immunostimulatory nucleic acids
WO2001036599A1 (en) 1999-11-19 2001-05-25 Chiron Corporation Microparticle-based transfection and activation of dendritic cells
US20030138453A1 (en) 2000-09-28 2003-07-24 O'hagan Derek Microparticles for delivery of heterologous nucleic acids
WO2002087541A1 (en) 2001-04-30 2002-11-07 Protiva Biotherapeutics Inc. Lipid-based formulations for gene transfer
AR045702A1 (es) * 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
US6861410B1 (en) 2002-03-21 2005-03-01 Chiron Corporation Immunological adjuvant compositions
CA2487274A1 (en) * 2002-05-06 2003-11-13 Nucleonics Inc. Spermine chemically linked to lipids and cell-specific targeting molecules as a transfection agent
AU2003302226A1 (en) 2002-09-24 2004-06-30 University Of Kentucky Research Foundation Nanoparticle-based vaccine delivery system containing adjuvant
CN1882693B (zh) 2003-09-15 2012-08-15 普洛体维生物治疗公司 聚乙二醇修饰的脂质化合物及其应用
US7303881B2 (en) 2004-04-30 2007-12-04 Pds Biotechnology Corporation Antigen delivery compositions and methods of use
AU2005259799A1 (en) 2004-07-02 2006-01-12 Protiva Biotherapeutics, Inc. Immunostimulatory siRNA molecules and uses therefor
US7749520B2 (en) 2004-07-07 2010-07-06 Statens Serum Institut Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids
BRPI0516974A (pt) 2004-10-21 2008-09-30 Wyeth Corp composição imunogênica compreendendo um polipeptìdeo; um método para induzir uma resposta imune contra staphylococcus epidermidis; um método para induzir uma resposta imune contra staphylococcus aureus; um método para a detecção e/ou identificação de staphylococcus epidermidis; um método para a detecção e/ou identificação de anticorpos para staphylococcus epidermidis
FR2885813B1 (fr) 2005-05-19 2008-01-11 Oreal Vectorisation de dsrna par des particules cationiques et leur utilisation sur modele de peau.
ES2385924T3 (es) 2006-02-02 2012-08-03 Allergan, Inc. Inhibidores de la actividad de CXCR4 para su uso en el tratamiento de trastornos oculares
CA2649630C (en) 2006-04-20 2016-04-05 Silence Therapeutics Ag Lipoplex formulations for specific delivery to vascular endothelium
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
AU2009236306B2 (en) 2008-04-17 2015-04-02 Pds Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids
JP5781929B2 (ja) 2008-07-15 2015-09-24 ノバルティス アーゲー 免疫原性の両親媒性ペプチド組成物
MX2011010045A (es) * 2009-03-25 2011-10-11 Novartis Ag Composicion farmaceutica que contiene un farmaco y siarn.
CN101538745B (zh) * 2009-04-22 2010-12-29 西南交通大学 一种可控释放基因药物的生物降解聚合物超细纤维的制备方法
WO2010142660A2 (en) * 2009-06-09 2010-12-16 Novartis Ag Drug delivery system
EP2451475A2 (en) 2009-07-06 2012-05-16 Novartis AG Self replicating rna molecules and uses thereof
WO2011076807A2 (en) * 2009-12-23 2011-06-30 Novartis Ag Lipids, lipid compositions, and methods of using them
JP5704163B2 (ja) 2010-03-12 2015-04-22 コニカミノルタ株式会社 分子間相互作用の検出方法およびその検出装置
FI4005592T3 (fi) 2010-07-06 2023-01-13 Virionin kaltaisia kuljetuspartikkeleita itsereplikoituville rna-molekyyleille
CA2804591C (en) * 2010-07-06 2019-01-22 Novartis Ag Cationic oil-in-water emulsions
US9636410B2 (en) 2011-07-06 2017-05-02 Glaxosmithkline Biologicals Sa Cationic oil-in-water emulsions
US9655845B2 (en) 2011-07-06 2017-05-23 Glaxosmithkline Biologicals, S.A. Oil-in-water emulsions that contain nucleic acids
JP6136343B2 (ja) 2012-06-12 2017-05-31 株式会社リコー 情報処理システム、情報処理方法、プログラム、及び記録媒体
WO2020000015A1 (en) 2018-06-29 2020-01-02 Integria Healthcare (Australia) Pty Limited Immunomodulatory compositions and uses thereof

Similar Documents

Publication Publication Date Title
RU2014104094A (ru) Катионные эмульсии масло-в-воде
US11965000B2 (en) Respiratory syncytial virus (RSV) vaccine
US10960070B2 (en) Prefusion coronavirus spike proteins and their use
JP2026040566A (ja) ＳＡＲＳ－ＣｏＶ－２ワクチン
Chen et al. Blood–brain barrier-and blood–brain tumor barrier-penetrating peptide-derived targeted therapeutics for glioma and malignant tumor brain metastases
US20220218815A1 (en) Coronavirus vaccine
JP2013531680A5 (cg-RX-API-DMAC10.html)
US20220378700A1 (en) Lipid Nanoparticles and Formulations Thereof for CAR mRNA Delivery
RU2468034C2 (ru) Иммуногенные композиции и способы
JP2014522840A5 (cg-RX-API-DMAC10.html)
US20220396556A1 (en) Lipid and Lipid Nanoparticle Formulation for Drug Delivery
RU2014104092A (ru) Эмульсии типа "масло в воде", которые содержат нуклеиновые кислоты
CN119947747A (zh) 流感病毒疫苗
TWI853485B (zh) 核酸-脂質奈米粒子及使用其之方法
Jiang et al. Specially-made lipid-based assemblies for improving transmembrane gene delivery: comparison of basic amino acid residue rich periphery
US20240228549A1 (en) Prefusion-stabilized lassa virus glycoprotein complex and its use
TW202438672A (zh) 四價流感疫苗之方法及組成物
EP4313115A1 (en) Optimized nucleotide sequences encoding the extracellular domain of human ace2 protein or a portion thereof
US20240374714A1 (en) Compositions and methods for multivalent immune responses
BR112021001460A2 (pt) trímeros de glicoproteína de filovírus estabilizados
JPWO2022244825A5 (cg-RX-API-DMAC10.html)
EP3586871A2 (en) Respiratory syncytial virus (rsv) vaccine
WO2026047603A1 (en) Sars-cov-2 immunogenic compositions
HK40090415A (en) Coronavirus vaccine
WO2025111442A1 (en) Lipid nanoparticles and methods of use for dna delivery